PMID- 19430296
OWN - NLM
STAT- MEDLINE
DCOM- 20090710
LR  - 20191210
IS  - 1533-4066 (Electronic)
IS  - 1052-9551 (Linking)
VI  - 18
IP  - 2
DP  - 2009 Jun
TI  - Bright-field in situ hybridization for HER2 gene amplification in breast cancer 
      using tissue microarrays: correlation between chromogenic (CISH) and automated 
      silver-enhanced (SISH) methods with patient outcome.
PG  - 88-95
LID - 10.1097/PDM.0b013e31816f6374 [doi]
AB  - INTRODUCTION: HER2 gene amplification or overexpression occurs in 15% to 25% of 
      breast cancers and has implications for treatment and prognosis. The most 
      commonly used methods for HER2 testing are fluorescence in situ hybridization 
      (FISH) and immunohistochemistry. FISH is considered to be the reference standard 
      and more accurately predicts response to trastuzumab, but is technically 
      demanding, expensive, and requires specialized equipment. In situ hybridization 
      is required to be eligible for adjuvant treatment with trastuzumab in Australia. 
      Bright-field in situ hybridization is an alternative to FISH and uses a 
      combination of in situ methodology and a peroxidase-mediated chromogenic 
      substrate such as diaminobenzidine [chromogenic in situ hybridization (CISH)] or 
      multimer technology coupled with enzyme metallography [silver-enhanced in situ 
      hybridization (SISH)] to create a marker visible under bright-field microscopy. 
      CISH was introduced into diagnostic testing in Australia in October 2006. SISH 
      methodology is a more recent introduction into the testing repertoire. An 
      evaluation of CISH and SISH performance to assess patient outcome were performed 
      using tissue microarrays. MATERIALS AND METHODS: Tissue microarrays were 
      constructed in duplicate using material from 593 patients with invasive breast 
      carcinoma and assessed using CISH and SISH. Gene amplification was assessed using 
      the American Society of Clinical Oncology/College of American Pathologists 
      guideline and Australian HER2 Advisory Board criteria (single probe: diploid, 1 
      to 2.5 copies/nucleus; polysomy >2.5 to 4 copies/nucleus; equivocal, >4 to 6 
      copies/nucleus; low-level amplification, >6 to 10 copies/nucleus and high-level 
      amplification >10 copies/nucleus; dual probe HER2/CHR17 ratio: nonamplified <1.8, 
      equivocal 1.8 to 2.2, amplified >2.2). RESULTS: Results were informative for 337 
      tissue cores comprising 230 patient samples. Concordance rates were 96% for HER2 
      single probe CISH and SISH and 95.5% for single probe CISH and dual probe 
      HER2/CHR17 SISH. Both bright-field methods correlated with immunohistochemistry 
      results and with breast cancer-specific survival. CONCLUSIONS: HER2 SISH testing 
      combines the advantages of automation and bright-field microscopy to facilitate 
      workflow within the laboratory, improves turnaround time, and correlates with 
      patient outcome.
FAU - Francis, Glenn D
AU  - Francis GD
AD  - Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Australia. 
      pathcare@msn.com.au
FAU - Jones, Mark A
AU  - Jones MA
FAU - Beadle, Geoffrey F
AU  - Beadle GF
FAU - Stein, Sandra R
AU  - Stein SR
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Diagn Mol Pathol
JT  - Diagnostic molecular pathology : the American journal of surgical pathology, part 
      B
JID - 9204924
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Breast Neoplasms/*diagnosis/genetics
MH  - Female
MH  - Gene Dosage
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - Mass Screening/*methods
MH  - Microarray Analysis/*methods
MH  - Middle Aged
EDAT- 2009/05/12 09:00
MHDA- 2009/07/11 09:00
CRDT- 2009/05/12 09:00
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/12 09:00 [pubmed]
PHST- 2009/07/11 09:00 [medline]
AID - 10.1097/PDM.0b013e31816f6374 [doi]
PST - ppublish
SO  - Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374.